+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diagnostic Radiopharmaceuticals for Alzheimer Disease Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Diagnostic Radiopharmaceuticals for Alzheimer Disease Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Diagnostic Radiopharmaceuticals for Alzheimer Disease Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6082406
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Alzheimer’s disease remains one of the most pressing neurological challenges of our time, affecting millions worldwide and imposing a profound burden on patients, caregivers, and healthcare systems. Diagnostic radiopharmaceuticals have revolutionized the way clinicians detect and monitor the progression of Alzheimer’s, enabling earlier intervention and more personalized treatment plans. By targeting hallmark biomarkers such as amyloid-beta plaques and tau proteins, these agents provide unparalleled molecular insights into disease pathology. Advances in positron emission tomography (PET) and single-photon emission computed tomography (SPECT), coupled with novel radiotracers, have propelled the field forward, offering greater specificity and sensitivity than ever before. As the diagnostic landscape evolves, stakeholders across academia, industry, and regulatory bodies must navigate complex scientific, technological, and economic factors to bring these life-changing tools to patients in need.

Transformative Shifts Reshaping the Alzheimer’s Imaging Landscape

Over the past decade, the Alzheimer’s diagnostic radiopharmaceutical market has witnessed transformative shifts that continue to redefine clinical practice and research paradigms. Notably, the transition from primarily amyloid-targeted imaging toward a dual focus that includes tau imaging has expanded the diagnostic toolkit, allowing for a more comprehensive assessment of disease stage and progression. Technological breakthroughs in hybrid imaging platforms and AI-powered analysis have further enhanced image resolution and quantification, ushering in an era of precision diagnostics. At the same time, emerging collaborations between pharmaceutical innovators, academic institutions, and imaging technology providers have fostered an environment conducive to rapid development and regulatory approval. Moreover, the rise of investigational agents and deep learning applications underscores the industry’s commitment to refining diagnostic accuracy and accelerating drug development pipelines. As a result, the field stands at the cusp of a new frontier where integrated data analytics and next-generation radiotracers will redefine Alzheimer’s disease management.

Cumulative Impact of 2025 US Tariffs on Diagnostic Radiopharmaceuticals

In early 2025, the implementation of revised United States tariffs on imported imaging components and precursor materials has exerted a cumulative impact on cost structures and supply chain dynamics. Increased duties on critical isotopes such as Fluorine-18 and Carbon-11 have translated into higher production expenses for PET radiopharmaceuticals, prompting manufacturers to revisit sourcing strategies and localize certain aspects of their supply chain. SPECT radiopharmaceutical developers have similarly felt the effects of tariffs on gamma-emitter precursors, compelling distributors to adjust pricing models and negotiate new tender agreements. Although these measures aim to protect domestic manufacturing, they have introduced temporary constraints on availability and heightened the urgency for operational efficiencies. Going forward, companies that proactively diversify their distribution channels and forge strategic partnerships with domestic isotope producers will be best positioned to mitigate tariff-driven disruptions and maintain seamless access to diagnostic agents.

Key Segmentation Insights for Alzheimer’s Imaging Radiopharmaceuticals

The Alzheimer’s diagnostic radiopharmaceutical market exhibits multifaceted segmentation that informs both development focus and commercial strategies. When partitioning by product type, the landscape encompasses PET radiopharmaceuticals, radiotracers, and SPECT radiopharmaceuticals. Within PET radiopharmaceuticals, a clear distinction emerges between FDA-approved diagnostics and investigational compounds that strive to capture novel biomarker profiles. Radiotracers divide into beta-emitters, prized for their high sensitivity in quantifying pathological substrates, and gamma-emitters, valued for broader availability and cost-effectiveness. In the SPECT domain, products are categorized as approved or under research, reflecting an evolving pipeline that bridges established imaging modalities and next-generation agents. Segmenting by disease diagnosis stage reveals that mild cognitive impairment diagnostics lead early intervention, while tools for moderate Alzheimer’s, pre-symptomatic detection, and severe Alzheimer’s management address critical junctures along the disease continuum. Biomarker target segmentation differentiates between amyloid imaging-both approved and in development-and tau imaging, which encompasses approved platforms and in-pipeline innovations aimed at correlating neurofibrillary tangles with clinical outcomes. Technology segmentation highlights advanced imaging algorithms, including AI-powered analysis and deep learning applications, alongside hybrid imaging systems, PET imaging technology, and SPECT imaging technology, each contributing to enhanced diagnostic precision. End-user segmentation spans academic and research institutes, biotechnology and pharmaceutical companies, diagnostic centers, and hospitals and clinics, reflecting diverse adoption drivers and budgetary considerations. Distribution channel segmentation includes direct tenders, distributors and wholesalers, and online sales, each route presenting unique regulatory and logistical requirements. Regulatory status categorization separates emerging products, FDA-approved products, and orphan drug status candidates, mapping the pathway to market authorization. Atom type segmentation focuses on Carbon-11 and Fluorine-18, isotopes that underpin PET imaging’s molecular insights. Finally, industry trends segmentation captures collaborations and partnerships, customization trends, and technological advancements that collectively steer innovation and adoption trajectories.

Regional Dynamics in Alzheimer’s Radiopharmaceutical Adoption

Regional dynamics play a pivotal role in shaping market adoption, reimbursement frameworks, and research investments for Alzheimer’s diagnostic radiopharmaceuticals. In the Americas, robust infrastructure for PET and SPECT imaging, combined with favorable reimbursement policies, fuels early adoption and ongoing clinical trials. Strong collaboration networks among academic centers and biotech firms further accelerate pipeline development. Europe, Middle East & Africa exhibits heterogeneous uptake, where leading Western European markets benefit from established regulatory pathways and government-funded screening initiatives, while emerging regions in the Middle East and Africa face hurdles related to infrastructure and specialized workforce. Across Asia-Pacific, rapid expansion of healthcare infrastructure, coupled with growing awareness of Alzheimer’s burden, drives significant investment in both diagnostic centers and local radiopharmaceutical production. Governments in key Asia-Pacific economies are streamlining approval processes for novel agents, fostering partnerships with global innovators to bridge technology gaps. As a result, Asia-Pacific is poised to register the fastest growth trajectory, while maturity in North America and select European markets sustains consistent demand.

Leading Players in Alzheimer’s Diagnostic Radiopharmaceuticals

The competitive landscape is anchored by established and emerging players that deliver a diversified portfolio of diagnostic radiopharmaceuticals for Alzheimer’s disease. Ashland Global Holdings Inc. brings expertise in specialty chemicals and radiolabeling components that underpin tracer synthesis. Avid Radiopharmaceuticals, a wholly owned subsidiary of a leading global pharmaceutical company, leads in amyloid imaging with an FDA-approved tracer portfolio. Bracco Imaging S.p.A. and Piramal Imaging GmbH each leverage decades of imaging expertise to offer both PET and SPECT solutions. Canon Inc. and Philips Healthcare invest in hybrid imaging platforms that integrate AI-driven analysis to enhance diagnostic workflows. Cerveau Technologies specializes in tau imaging agents, advancing pipeline candidates toward regulatory milestones. Curium Pharma and GE Healthcare maintain robust isotope production capabilities that ensure consistent supply for global clinical networks. General Electric Company and Siemens Healthineers AG drive innovation in PET and SPECT hardware, supporting next-generation tracer applications. Jubilant Pharma Holdings and Jubilant Radiopharma focus on distribution and contract manufacturing services, while Lantheus Medical Imaging and Navidea Biopharmaceuticals develop targeted agents for specific biomarker profiles. NeuraCeq and Sterling Pharmaceuticals contribute niche tracer technologies that address emerging diagnostic needs. Collectively, these companies shape a dynamic ecosystem where scientific collaboration and competitive differentiation work hand in hand to propel the field forward.

Actionable Recommendations for Industry Leaders

Industry leaders must adopt strategic initiatives that align with evolving regulatory, technological, and market landscapes. First, prioritizing flexible manufacturing models that incorporate local isotope production and modular synthesis units will shield operations from tariff-induced cost pressures and supply chain disruptions. Concurrently, fostering partnerships with AI solution providers to integrate advanced imaging algorithms and deep learning applications will accelerate the translation of high-resolution data into actionable clinical insights. Companies should also allocate resources toward pipeline expansion, focusing on tau imaging candidates and dual-target tracers that capture both amyloid and tau pathology. Engaging early with regulatory authorities through accelerated approval pathways and orphan drug designations will streamline time to market for novel agents targeting pre-symptomatic and severe Alzheimer’s stages. To optimize market penetration, firms must tailor distribution strategies by leveraging direct tender opportunities in mature markets and online sales platforms in regions with digital infrastructure. Finally, establishing cross-sector collaborations with academic institutions and biotechnology partners will foster innovation ecosystems, enabling co-development of next-generation radiopharmaceuticals and co-funded clinical validation studies.

Conclusion: Navigating Future Opportunities

As the Alzheimer’s diagnostic radiopharmaceutical market continues to evolve, stakeholders must remain agile and forward-thinking. The convergence of advanced imaging technologies, robust segmentation strategies, and shifting regulatory environments underscores a period of unparalleled opportunity. By capitalizing on emerging tau imaging agents, integrating AI-driven quantification tools, and navigating tariff challenges with strategic supply chain adaptations, companies can secure competitive advantage. Furthermore, regional insights highlight the need for market-specific approaches, from bolstering production capabilities in Asia-Pacific to optimizing reimbursement frameworks in the Americas and European territories. Ultimately, the organizations that combine scientific rigor with operational excellence will drive the next wave of diagnostic breakthroughs and meaningfully improve patient outcomes.

Market Segmentation & Coverage

This research report categorizes the Diagnostic Radiopharmaceuticals for Alzheimer Disease Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • PET Radiopharmaceuticals
    • FDA Approved
    • Investigational
  • Radiotracers
    • Beta-Emitters
    • Gamma-Emitters
  • SPECT Radiopharmaceuticals
    • Approved
    • Under Research
  • Mild Cognitive Impairment
  • Moderate Alzheimer’s
  • Pre-Symptomatic
  • Severe Alzheimer’s
  • Amyloid Imaging
    • Approved
    • In Development
  • Tau Imaging
    • Approved
    • In Pipeline
  • Advanced Imaging Algorithms
    • AI-Powered Analysis
    • Deep Learning Applications
  • Hybrid Imaging
  • PET Imaging Technology
  • SPECT Imaging Technology
  • Academic & Research Institutes
  • Biotechnology & Pharmaceutical Companies
  • Diagnostic Centers
  • Hospitals & Clinics
  • Direct Tenders
  • Distributors and Wholesalers
  • Online Sales
  • Emerging Products
  • FDA Approved Products
  • Orphan Drug Status
  • Carbon-11
  • Fluorine-18
  • Collaborations & Partnerships
  • Customization Trends
  • Technological Advancements

This research report categorizes the Diagnostic Radiopharmaceuticals for Alzheimer Disease Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Diagnostic Radiopharmaceuticals for Alzheimer Disease Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Ashland Global Holdings Inc.
  • Avid Radiopharmaceuticals, Inc. (a wholly owned subsidiary of Eli Lilly and Company)
  • Bracco Imaging S.p.A.
  • Canon Inc.
  • Cerveau Technologies, Inc.
  • Curium Pharma
  • GE Healthcare
  • General Electric Company
  • Jubilant Pharma Holdings Inc.
  • Jubilant Radiopharma
  • Lantheus Medical Imaging, Inc.
  • Navidea Biopharmaceuticals, Inc.
  • NeuraCeq
  • Philips Healthcare
  • Piramal Imaging GmbH
  • Siemens Healthineers AG
  • Sterling Pharmaceuticals

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Product Type
8.1. Introduction
8.2. PET Radiopharmaceuticals
8.2.1. FDA Approved
8.2.2. Investigational
8.3. Radiotracers
8.3.1. Beta-Emitters
8.3.2. Gamma-Emitters
8.4. SPECT Radiopharmaceuticals
8.4.1. Approved
8.4.2. Under Research
9. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Disease Diagnosis Stage
9.1. Introduction
9.2. Mild Cognitive Impairment
9.3. Moderate Alzheimer’s
9.4. Pre-Symptomatic
9.5. Severe Alzheimer’s
10. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Biomarker Target
10.1. Introduction
10.2. Amyloid Imaging
10.2.1. Approved
10.2.2. In Development
10.3. Tau Imaging
10.3.1. Approved
10.3.2. In Pipeline
11. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Technology
11.1. Introduction
11.2. Advanced Imaging Algorithms
11.2.1. AI-Powered Analysis
11.2.2. Deep Learning Applications
11.3. Hybrid Imaging
11.4. PET Imaging Technology
11.5. SPECT Imaging Technology
12. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by End User
12.1. Introduction
12.2. Academic & Research Institutes
12.3. Biotechnology & Pharmaceutical Companies
12.4. Diagnostic Centers
12.5. Hospitals & Clinics
13. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Distribution Channel
13.1. Introduction
13.2. Direct Tenders
13.3. Distributors and Wholesalers
13.4. Online Sales
14. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Regulatory Status
14.1. Introduction
14.2. Emerging Products
14.3. FDA Approved Products
14.4. Orphan Drug Status
15. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Atom Type
15.1. Introduction
15.2. Carbon-11
15.3. Fluorine-18
16. Diagnostic Radiopharmaceuticals for Alzheimer Disease Market, by Industry Trends
16.1. Introduction
16.2. Collaborations & Partnerships
16.3. Customization Trends
16.4. Technological Advancements
17. Americas Diagnostic Radiopharmaceuticals for Alzheimer Disease Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. Ashland Global Holdings Inc.
20.3.2. Avid Radiopharmaceuticals, Inc. (a wholly owned subsidiary of Eli Lilly and Company)
20.3.3. Bracco Imaging S.p.A.
20.3.4. Canon Inc.
20.3.5. Cerveau Technologies, Inc.
20.3.6. Curium Pharma
20.3.7. GE Healthcare
20.3.8. General Electric Company
20.3.9. Jubilant Pharma Holdings Inc.
20.3.10. Jubilant Radiopharma
20.3.11. Lantheus Medical Imaging, Inc.
20.3.12. Navidea Biopharmaceuticals, Inc.
20.3.13. NeuraCeq
20.3.14. Philips Healthcare
20.3.15. Piramal Imaging GmbH
20.3.16. Siemens Healthineers AG
20.3.17. Sterling Pharmaceuticals
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET MULTI-CURRENCY
FIGURE 2. DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET MULTI-LANGUAGE
FIGURE 3. DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2024 VS 2030 (%)
FIGURE 24. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY FDA APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INVESTIGATIONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BETA-EMITTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY GAMMA-EMITTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY UNDER RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY MODERATE ALZHEIMER’S, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRE-SYMPTOMATIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SEVERE ALZHEIMER’S, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY IN PIPELINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AI-POWERED ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DEEP LEARNING APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY HYBRID IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET IMAGING TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT IMAGING TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DIRECT TENDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTORS AND WHOLESALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY EMERGING PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY FDA APPROVED PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ORPHAN DRUG STATUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY CARBON-11, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY FLUORINE-18, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY COLLABORATIONS & PARTNERSHIPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY CUSTOMIZATION TRENDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2018-2030 (USD MILLION)
TABLE 107. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 109. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 110. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 111. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2018-2030 (USD MILLION)
TABLE 112. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2018-2030 (USD MILLION)
TABLE 113. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, 2018-2030 (USD MILLION)
TABLE 114. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, 2018-2030 (USD MILLION)
TABLE 115. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, 2018-2030 (USD MILLION)
TABLE 117. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2018-2030 (USD MILLION)
TABLE 120. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2018-2030 (USD MILLION)
TABLE 121. CANADA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2018-2030 (USD MILLION)
TABLE 122. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 124. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 125. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 126. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2018-2030 (USD MILLION)
TABLE 127. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2018-2030 (USD MILLION)
TABLE 128. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, 2018-2030 (USD MILLION)
TABLE 129. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, 2018-2030 (USD MILLION)
TABLE 130. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, 2018-2030 (USD MILLION)
TABLE 132. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2018-2030 (USD MILLION)
TABLE 135. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2018-2030 (USD MILLION)
TABLE 136. MEXICO DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 172. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2018-2030 (USD MILLION)
TABLE 174. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2018-2030 (USD MILLION)
TABLE 184. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 186. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 187. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 188. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2018-2030 (USD MILLION)
TABLE 189. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2018-2030 (USD MILLION)
TABLE 190. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, 2018-2030 (USD MILLION)
TABLE 191. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, 2018-2030 (USD MILLION)
TABLE 192. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 193. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, 2018-2030 (USD MILLION)
TABLE 194. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2018-2030 (USD MILLION)
TABLE 197. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2018-2030 (USD MILLION)
TABLE 198. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2018-2030 (USD MILLION)
TABLE 199. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 200. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 201. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 202. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 203. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2018-2030 (USD MILLION)
TABLE 204. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2018-2030 (USD MILLION)
TABLE 205. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, 2018-2030 (USD MILLION)
TABLE 206. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, 2018-2030 (USD MILLION)
TABLE 207. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 208. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, 2018-2030 (USD MILLION)
TABLE 209. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2018-2030 (USD MILLION)
TABLE 212. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2018-2030 (USD MILLION)
TABLE 213. INDIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2018-2030 (USD MILLION)
TABLE 214. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 215. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 216. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 217. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 218. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2018-2030 (USD MILLION)
TABLE 219. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2018-2030 (USD MILLION)
TABLE 220. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, 2018-2030 (USD MILLION)
TABLE 222. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 223. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2018-2030 (USD MILLION)
TABLE 229. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 231. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 232. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 233. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISEASE DIAGNOSIS STAGE, 2018-2030 (USD MILLION)
TABLE 234. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY BIOMARKER TARGET, 2018-2030 (USD MILLION)
TABLE 235. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY AMYLOID IMAGING, 2018-2030 (USD MILLION)
TABLE 236. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TAU IMAGING, 2018-2030 (USD MILLION)
TABLE 237. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 238. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ADVANCED IMAGING ALGORITHMS, 2018-2030 (USD MILLION)
TABLE 239. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY REGULATORY STATUS, 2018-2030 (USD MILLION)
TABLE 242. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY ATOM TYPE, 2018-2030 (USD MILLION)
TABLE 243. JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY INDUSTRY TRENDS, 2018-2030 (USD MILLION)
TABLE 244. MALAYSIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 245. MALAYSIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 246. MALAYSIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY RADIOTRACERS, 2018-2030 (USD MILLION)
TABLE 247. MALAYSIA DIAGNOSTIC RADIOPHARMACEUTICALS FOR ALZHEIMER DISEASE MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)

Companies Mentioned

  • Ashland Global Holdings Inc.
  • Avid Radiopharmaceuticals, Inc. (a wholly owned subsidiary of Eli Lilly and Company)
  • Bracco Imaging S.p.A.
  • Canon Inc.
  • Cerveau Technologies, Inc.
  • Curium Pharma
  • GE Healthcare
  • General Electric Company
  • Jubilant Pharma Holdings Inc.
  • Jubilant Radiopharma
  • Lantheus Medical Imaging, Inc.
  • Navidea Biopharmaceuticals, Inc.
  • NeuraCeq
  • Philips Healthcare
  • Piramal Imaging GmbH
  • Siemens Healthineers AG
  • Sterling Pharmaceuticals

Methodology

Loading
LOADING...

Related Topics

Related Reports

SPECT & PET Radiopharmaceuticals Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

SPECT & PET Radiopharmaceuticals Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global, United States Global, United States
From
Radiopharmaceuticals Market - Products and Applications - Product Image

Radiopharmaceuticals Market - Products and Applications

  • Report
  • 307 Pages
  • Global
From
Radiopharmaceutical Theranostics Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Radiopharmaceutical Theranostics Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Radiopharmaceuticals in PET Imaging Market - A Global and Regional Analysis: Focus on Radioisotope Type, Application, End User, and Country-Level Analysis - Analysis and Forecast, 2025-2035 - Product Image

Radiopharmaceuticals in PET Imaging Market - A Global and Regional Analysis: Focus on Radioisotope Type, Application, End User, and Country-Level Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets - Product Image

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

  • Report
  • 125 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.